BioRestorative Therapies, Inc. (BRTX)

1,4200 -0,0500 (-3,40%) Alla chiusura: 04:00PM EDT

BioRestorative Therapies, Inc.

40 Marcus Drive
Suite 1
Melville, NY 11747
United States
631 760 8100
https://www.biorestorative.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 11

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Lance Alstodt	Chairman of the Board, President & CEO	954,17k	N/D	1971
Mr. Robert Eugene Kristal	Chief Financial Officer	368,12k	N/D	1968
Mr. Francisco J. Silva	Chief Scientist, VP of Research & Development, Secretary and Director	891,67k	N/D	1975
Mr. Robert Paccasassi	Vice President of Quality Assurance & Regulatory Compliance	233,95k	N/D	1969
Dr. Wayne J. Olan M.D.	Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs relate to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is based in Melville, New York.

Governance aziendale

L'ISS Governance QualityScore di BioRestorative Therapies, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.